Wilmington, Delaware, United States, Transparency Market Research Inc. -, Aug. 26, 2024 (GLOBE NEWSWIRE) -- The global aplastic anemia market (再生不良性貧血市場) was projected to attain US$ 6.7 billion in 2023. It is likely to garner a 4.3% CAGR from 2024 to 2034, and by 2034, the market is expected to attain US$ 10.8 billion.
The term "aplastic anemia" refers to a potentially fatal hemopoiesis failure marked by pancytopenia and hypocellular bone marrow. The primary causes of acquired aplastic anemia are viruses. This illness can also be passed down from the mother to her offspring.
The major competitors in the aplastic anemia market are introducing novel medications to treat the condition and striving to minimize side effects by performing clinical studies. The regulatory agencies also hope for expedited approvals in order to increase the quantity of fully developed aplastic therapeutic medicines available.
Download Sample PDF Brochure: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=86040
Key Findings of Market Report
- When the body stops producing enough blood cells, aplastic anemia begins to occur.
- In turn, it turns out that the patients are more susceptible to infections and bleeding.
- The purpose of clinical studies is to evaluate the effectiveness of romiplostim plus cyclophosphamide in order to address the challenges and problems associated with aplastic anemia.
- Immunosuppressive medication and allogeneic stem cell transplantation have raised patient survival rates by five years, according to the National Institutes of Health.
Market Trends For Aplastic Anemia
- Numerous aspects of aplastic anemia are being studied by researchers, including the effectiveness of novel combination treatments, the ideal dose of immunosuppressant after stem cell transplantation, and novel techniques for stem cell transplantation that reduce complications and improve outcomes.
- Clinical trials are being conducted on methylprednisolone, filgrastim, cyclosporine, horse anti-thymocyte globulin, and/or pegfilgrastim or pegfilgrastim biosimilar as treatments for people with aplastic anemia or intermediate- or low-risk myelodysplastic syndrome.
- In addition, a conditioning regimen based on treosulfan is used in the treatment of bone marrow failure diseases prior to bone marrow or blood transplantation (BMT CTN 1904).
- The market potential for aplastic anemia are therefore being driven by an increase in the frequency of clinical studies, as previously noted.
Global Market for Aplastic Anemia: Regional Outlook
Various reasons propel the aplastic anemia market growth throughout the regions. These are:
- According to the most recent aplastic anemia market data, North America accounted for the majority of the acquired aplastic anemia landscape in 2023, and this trend is likely to continue during the forecast period. This is due to significant research being undertaken on aplastic anemia therapy in the United States and Canada.
- Asia Pacific's aplastic anemia market is growing because nations like India have a large number of anemic patients. Various awareness efforts on the need to prevent aplastic anemia are being performed, and they are keeping up with the growth of the treatment sector.
Unlock Growth Potential in Your Industry! Download PDF Brochure: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=86040
Global Aplastic Anemia Market: Key Players
Companies that deal with aplastic anemia introduce new products and then wait for regulatory agencies to approve them quickly. For example, as of April 2021, the U.S. FDA's Likelihood of Approval (LoA) for Amgen's Nplate (romiplostim) to treat aplastic anemia increased by 11 points.
The following companies are well-known participants in the global aplastic anemia market:
- Eisai Co., Ltd.
- Pfizer Inc.
- Sanofi S.A.
- Teva Pharmaceutical Industries Ltd.
- Novartis AG
- Allergan plc
- Merz Pharma GmbH & Co. KGaA
- Johnson & Johnson Services Inc.
- F. Hoffmann-La Roche AG
- AbbVie Inc.
- Takeda Pharmaceutical Company Limited
- Bayer AG
- Others
Key developments:
- The Enjaymo (sutimlimab-jome) injection was authorized by the FDA in February 2022 with the goal of lowering the requirement for red blood cell transfusions in individuals with cold agglutinin disease (CAD).
Global Aplastic Anemia Market (Markt für aplastische Anämie) Segmentation
- Disease Type
- Acquired Aplastic Anemia
- Inherited Aplastic Anemia
- Treatment Type
- Bone Marrow Transfusion
- Blood Transfusion
- Drug Therapy
- Mode of Administration
- Injectable
- Oral
- Others
- End-user
- Hospitals
- Specialty Clinics
- Others
- By Region
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East & Africa
Purchase the Report for Market-Driven Insights:
https://www.transparencymarketresearch.com/checkout.php?rep_id=86040<ype=S
Have a Look at More Valuable Insights of Healthcare
Hybrid Operating Room Market (하이브리드 수술실 시장): The global Hybrid Operating Room Market is expected to grow at a CAGR of 7.7% from 2022 to 2031. The hybrid operating room is a surgical theatre or space with medical equipment such as fix C-arms, MRI scanners, and CT scanners used for interventional imaging procedures or minimally invasive surgeries.
Wearable Breast Pumps Market (Marché des tire-lait portables): The global wearable breast pumps market was estimated at a value of US$ 554.5 million in 2022. It is anticipated to register a 8.2% CAGR from 2023 to 2031 and by 2031, the market is likely to attain US$ 1.2 billion by 2032.
About Transparency Market Research
Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Contact:
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Email: sales@transparencymarketresearch.com
Follow Us: LinkedIn| Twitter| Blog | YouTube
